The immunogenicity and safety of zoster vaccine in Taiwanese adults
Journal
Vaccine
Journal Volume
33
Journal Issue
13
Pages
1515-1517
Date Issued
2015
Author(s)
Abstract
The efficacy and safety of ZOSTAVAX? in subjects 60 years of age and older was established in the Shingles Prevention Study (SPS) and in subjects 50 to 59 years of age in the ZOSTAVAX? Efficacy and Safety Trial (ZEST). We evaluated the safety and immunogenicity of ZOSTAVAX? in a total of 150 Taiwanese subjects ?50 years of age, who received a single dose of ZOSTAVAX?. gpELISA was used to determine geometric mean titers (GMT) of the varicella-zoster virus (VZV) antibody. The geometric mean fold rise (GMFR) of the VZV antibody from the pre-vaccination to the 4 week post-vaccination time point was calculated. There was an overall increase in GMT from 128.45 to 391.85 at 4 weeks post-vaccination. The estimated GMFR was 3.05 (95% CI: 2.60 to 3.57).There were no serious adverse events for 28 days following vaccination. This study demonstrated the safety and immunogenicity of ZOSTAVAX? among healthy Taiwanese adults. ? 2015 Elsevier Ltd.
SDGs
Other Subjects
herpes zoster immunoglobulin; varicella zoster vaccine; varicella zoster vaccine; virus antibody; adult; aged; antibody titer; Article; asthenia; dizziness; drug determination; drug efficacy; drug safety; drug tolerability; female; geometry; human; immunogenicity; major clinical study; male; middle aged; pain; pharyngitis; priority journal; single drug dose; Taiwanese; vaccination; biosynthesis; blood; herpes zoster; immunology; Taiwan; vaccination; Varicella zoster virus; very elderly; Adult; Aged; Aged, 80 and over; Antibodies, Viral; Female; Herpes Zoster; Herpes Zoster Vaccine; Herpesvirus 3, Human; Humans; Male; Middle Aged; Taiwan; Vaccination
Publisher
Elsevier Ltd
Type
journal article